Start Submission Become a Reviewer

Reading: Real-world clinical outcomes of anticancer treatments in patients with advanced melanoma in ...

Download

A- A+
Alt. Display

Cross Sectional Study

Real-world clinical outcomes of anticancer treatments in patients with advanced melanoma in China: retrospective, observational study

Authors:

Chuanliang Cui,

Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Chuanliang

MD

X close

Xieqiao Yan,

Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Xieqiao

MD

X close

Shusen Liu,

Department of Medical Oncology, MSD China, Beijing, CN
About Shusen

MD

X close

Anne C. Deitz,

Department of Medical Oncology, Merck & Co. Inc., Kenilworth, NJ, US
About Anne C.

PhD

X close

Lu Si,

Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Lu

MD

X close

Zhihong Chi,

Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Zhihong

MD

X close

Xinan Sheng,

Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Xinan

MD

X close

Bin Lian,

Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Bin

MD

X close

Jianfeng Li,

Department of Medical Oncology, MSD China, Beijing, CN
About Jianfeng

MD

X close

Jun Ge,

Department of Medical Oncology, MSD China, Beijing, CN
About Jun

MD

X close

Xuan Wang,

Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Xuan

MD

X close

Lili Mao,

Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Lili

MD

X close

Bixia Tang,

Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Bixia

MD

X close

Li Zhou,

Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Li

MD

X close

Xue Bai,

Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Xue

MD

X close

Siming Li,

Department of Urology and Melanoma, Beijing Cancer Hospital, Beijing, CN
About Siming

MD

X close

Ben Li,

Department of Medical Oncology, MSD China, Beijing, CN
About Ben

MD

X close

Haiyan Wu,

Department of Medical Oncology, MSD China, Beijing, CN
About Haiyan

MD

X close

Jun Guo

Department of Urology and Melanoma, Peking University Cancer Hospital & Institute, 52 # Fucheng Road, Haidian District, Beijing, CN
About Jun

MD

X close

Abstract

Introduction: Treatment options for advanced melanoma in China are lacking, particularly second-line therapies. The aim of this retrospective observational study was to describe the real-world effectiveness of available anticancer therapies in patients with locally advanced/metastatic melanoma in China.

Methods: Adult patients with unresectable stage III or IV melanoma treated between January 1, 2014, and December 31, 2015, at the Beijing Cancer Hospital (BCH) were eligible (data cutoff: December 31, 2017). Data were obtained from patient electronic medical records. Responders were adjudicated per Response Evaluation Criteria in Solid Tumors, version 1.1. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method.

Results: Of 248 eligible patients, 221 and 116 were treated with anticancer therapies in first-line and second-line settings, respectively (89 received both at BCH). Approximately 95% of patients had stage IV melanoma; 40.7% had acral melanoma, and 30.6% had mucosal histology. By data cutoff, 195 of 248 (78.6%) patients had died. Median OS for all patients was 10.5 months; 12-month OS rate was 43.9%. In the first-line setting, the objective response rate was 6.3% (95% confidence interval, 3.5%–10.4%) and the median duration of response was 9.1 months. Median PFS was 3.5 months and 12-month PFS rate was 10.6%; median OS was 10.5 months and 12-month OS rate was 43.5%. In the second-line setting, objective response rate was 3.4% (95% confidence interval, 0.9%–8.6%) and median duration of response was 7.5 months. Median PFS was 2.3 months and 12-month PFS rate was 5.2%; median OS was 7.5 months and 12-month OS rate was 30.5%.

Conclusion: In China, first-line and second-line anticancer therapy seems to be associated with suboptimal clinical outcomes in advanced melanoma, indicating a need for effective therapies.

How to Cite: Cui C, Yan X, Liu S, Deitz AC, Si L, Chi Z, et al.. Real-world clinical outcomes of anticancer treatments in patients with advanced melanoma in China: retrospective, observational study. International Journal of Surgery: Oncology. 2019;4(6):e76. DOI: http://doi.org/10.1097/IJ9.0000000000000076
2
Views
Published on 24 Oct 2019.
Peer Reviewed

Downloads

  • PDF (EN)